Cargando…

Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow

Using an iron overload mouse model, we explored the protective effect of deferasirox (DFX) and N-acetyl-L-cysteine (NAC) on injured bone marrow hematopoietic stem/progenitor cells (HSPC) induced by iron overload. Mice were intraperitoneally injected with 25 mg iron dextran every 3 days for 4 weeks t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, J.C., Zhang, Y.C., Zhao, M.F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Divulgação Científica 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649863/ https://www.ncbi.nlm.nih.gov/pubmed/29069221 http://dx.doi.org/10.1590/1414-431X20176087

Ejemplares similares

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox
por: Lescano, Manuel A, et al.
Publicado: (2017)

Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine
por: Wongjaikam, Suwakon, et al.
Publicado: (2017)

ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice
por: Chai, Xiao, et al.
Publicado: (2015)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Effects of Iron Overload on the Bone Marrow Microenvironment in Mice
por: Zhang, Yuchen, et al.
Publicado: (2015)

Corrigendum: ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice
por: Chai, Xiao, et al.
Publicado: (2017)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Iron Chelation Therapy with Deferasirox Results in Improvement of Liver Enzyme Level in Patients with Iron Overload-Associated Liver Dysfunction
por: Miura, Yasuo, et al.
Publicado: (2010)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
por: Daar, Shahina, et al.
Publicado: (2009)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
por: Chalmers, Anna W, et al.
Publicado: (2016)

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2018)

Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis
por: Qadah, Talal
Publicado: (2022)

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
por: Porter, John B, et al.
Publicado: (2011)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Evaluation of protective effect of N-acetyl cysteine on arsenic-induced hepatotoxicity
por: Hemalatha, Pudari, et al.
Publicado: (2013)

N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases
por: Martinez-Banaclocha, Marcos
Publicado: (2022)

Protective Effect of N-Acetyl Cysteine on Chlorpyrifos-Induced Testicular Toxicity in Mice
por: Kheradmandi, Rasoul, et al.
Publicado: (2019)

N-Acetyl Cysteine as an Adjunct in the Treatment of Tuberculosis
por: Ejigu, Dawit A., et al.
Publicado: (2020)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

Inhibition of iron overload-induced apoptosis and necrosis of bone marrow mesenchymal stem cells by melatonin
por: Yang, Fan, et al.
Publicado: (2017)

N-Acetyl L-Cysteine does not protect mouse ears from the effects of noise*
por: Davis, Rickie R, et al.
Publicado: (2010)

Does N-acetyl Cysteine Have Protective Effects in Acute Aluminum Phosphide Poisoning?
por: Nakhaee, Samaneh, et al.
Publicado: (2017)

Drug-Induced Liver Injury: Clinical Evidence of N-Acetyl Cysteine Protective Effects
por: Ntamo, Yonela, et al.
Publicado: (2021)

Efficacy of N-Acetyl Cysteine in Traumatic Brain Injury
por: Eakin, Katharine, et al.
Publicado: (2014)

A Review on Various Uses of N-Acetyl Cysteine
por: Mokhtari, Vida, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h8s735fte9pgfjgumllelq8788